Bevacizumab Induces Ferroptosis and Enhances CD8⁺ T Cell Immune Activity in Liver Cancer via Modulating HAT1 and Increasing IL-9

Researchers investigated whether and how bevacizumab regulated ferroptosis and immune activity in liver cancer. They performed RNA-sequencing in bevacizumab-treated human liver cancer cell line HepG2 cells, and found that bevacizumab significantly altered the expression of a number of genes including VEGF, PI3K, HAT1, SLC7A11 and IL-9 in liver cancer, bevacizumab upregulated 37 ferroptosis-related drivers.